Robert Janigian, MD
Retina Specialist · Providence, RINPI 1831195965
Payments from drug & device makers
Across 16 payments — averaging $88.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$438
- Novartis$197
- Genentech USA, Inc.$143
- Alcon$142
- Eyepoint US, Inc.$141
- Bausch & Lomb Americas Inc.$110
- plus $243 from 4 others
What the payments were for
- Food & beverage$1,37897%
- Gifts$373%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 4 | $438 |
| Novartis | 2 | $197 |
| Genentech USA, Inc. | 1 | $143 |
| Alcon | 2 | $142 |
| Eyepoint US, Inc. | 2 | $141 |
| Bausch & Lomb Americas Inc. | 1 | $110 |
| Mallinckrodt Hospital Products Inc. | 1 | $109 |
| Apellis Pharmaceuticals, Inc. | 1 | $98 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few retina specialist providers in Rhode Islandto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 230 | $10,113 |
| Bromfenac Sodium | 48 | $8,144 |
| Difluprednate | 31 | $2,277 |
| Latanoprost | 132 | $2,075 |
| Timolol Maleate | 86 | $1,173 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 52 | $1,138 |
| Brimonidine Tartrate | 79 | $1,125 |
| Atropine Sulfate | 16 | $902 |
| MethotrexateMethotrexate Sodium | 28 | $635 |
| Ketorolac Tromethamine | 19 | $629 |
| ValacyclovirValacyclovir Hcl | 11 | $462 |
| Dorzolamide Hcl | 25 | $385 |
| MoxifloxacinMoxifloxacin Hcl | 15 | $362 |
| Ofloxacin | 24 | $282 |
| Prednisone | 21 | $174 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Providence
- Jacob DukerProvidence$8K
- Brian SavoieProvidence$2K
- Altin PaniProvidence$359
- Scott GreenbergProvidence$75
- Harold WoodcomeProvidence$25
- Dean LoporchioCranston$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.